N/A
N=440
Examining the Generality of Laboratory-based Findings and Their Moderators in the ITC Study
Cigarette Smoking · Nicotine Vaping
Bottom Line
View on ClinicalTrials.gov: NCT06456671 ↗Enrolled (actual)
440
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Proportion of Budget Spent - CIGARETTES — 89.9; 44.5; 87.3; 47.4 percentage of budget spent — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- All nicotine/ tobacco products at market price (Other); Nicotine vaping products at 1/2 market price (Other); Heated tobacco products at 1/2 market price. (Other); Nicotine pouch products at 1/2 market price. (Other)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Virginia Polytechnic Institute and State University
- Primary completion
- Jan 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Budget Spent - CIGARETTES |
89.9; 44.5; 87.3; 47.4; 76.1; 45.9 | <0.001 sig |
| SECONDARY Alternative Product Consumption - E-CIGARETTES |
40.9; 553.4; 105.1; 617.8; 128.5; 828.3 | — |
| SECONDARY Alternative Product Consumption - HTP |
2.3; 4.4; 9.5; 4.9; 2.2; 3.0 | — |
| SECONDARY Alternative Product Consumption - Nicotine Pouches |
0.1; 3.4; 0.9; 4.6; 0.5; 3.5 | — |
| SECONDARY Alternative Product Consumption - Nicotine Replacement Therapy |
0.6; 2.8; 2.6; 4.2; 0.4; 3.7 | — |
| SECONDARY Alternative Product Consumption - Oral Tobacco Products |
0.1; 1.7; 0.4; 1.3; 0.1; 1.9 | — |
Summary
This study will investigate the relative appeal (abuse liability) of novel tobacco products, how the appeal is modulated by relative price, user type, and how novel products may substitute for one another.
Eligibility Criteria
Inclusion Criteria
- From CA, US, or EN
- At least 21 years old
- Smoking daily
- Smoking mostly or about equal amounts of factory-made cigarettes
- Does not currently vape (for exclusive smokers only)
- Vapes Daily (for dual users only)
Exclusion Criteria
- There will be no additional exclusion criteria for this study.
Data sourced from ClinicalTrials.gov (NCT06456671). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.